Real-World Data Show Antibody-Drug Conjugate Still Works in Late-Stage Triple-Negative Breast Cancer

Triple-negative breast cancer is among the most feared diagnoses in oncology. Lacking the three molecular handles—estrogen receptor, progesterone receptor, and HER2—that drive targeted therapies for other breast cancer subtypes, it leaves patients and their doctors with few options once standard chemotherapy begins to fail. When the disease spreads to distant organs, the clock accelerates: median survival has historically been measured in months rather than years. Against this grim backdrop, a new real-world study from Central Europe offers a measured but meaningful dose of hope, showing that a modern antibody-drug conjugate continues to deliver clinical benefit even in patients whose tumors have already been battered by multiple rounds of treatment.

The drug in question is sacituzumab govitecan, an engineered molecule that fuses two very different components into a single therapeutic agent. One end is an antibody that recognizes TROP-2, a cell-surface protein found at high levels on many epithelial cancers, including the majority of triple-negative breast tumors. The other end is SN-38, the active metabolite of the widely used chemotherapy drug irinotecan, which poisons dividing cells by blocking the topoisomerase I enzyme and triggering lethal DNA damage. A cleavable chemical linker holds the two together, designed to remain stable in the bloodstream and then release its toxic payload once the antibody docks onto a tumor cell and the complex is internalized. The result is a delivery system that concentrates a potent cell-killing drug where it is needed most, while sparing healthy tissue more effectively than conventional chemotherapy ever could.

Sacituzumab govitecan earned regulatory approval on the strength of randomized clinical trials, but trial populations are notoriously selective. Patients enrolled in pivotal studies tend to be younger, fitter, and free of the organ dysfunction and competing illnesses that characterize many people treated in everyday clinics. The question of whether the drug performs as well in the messy reality of routine oncology care is therefore far from academic. That is precisely the question addressed by a team of researchers led by Marcin Kubeczko of the Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice, Poland, and Mirosława Püsküllüoğlu of the institute’s Krakow branch, in a secondary analysis of the CEBCC-102 real-world cohort published in BMC Cancer.

The study pooled data from cancer centers across Poland, the Czech Republic, and Slovakia, creating one of the larger real-world datasets on this drug in the region. The researchers restricted their analysis to patients who received sacituzumab govitecan as third-line or later systemic therapy for metastatic disease—a group so heavily pretreated that many had exhausted nearly every standard option. To qualify, patients needed either at least three prior chemotherapy lines for metastatic disease, or prior chemotherapy given before surgery with the intent to cure followed by at least two further chemotherapy lines after relapse. In total, 107 patients met these criteria. Sixty-seven of them had received exactly three prior chemotherapy lines, while forty had endured four or more, a testament to both the tenacity of the disease and the determination of the clinicians treating it.

The headline numbers tell a story of modest but genuine activity. After a median follow-up of 19.6 months, estimated using the reverse Kaplan–Meier method, patients treated with sacituzumab govitecan lived a median of 4.1 months before their disease progressed, with 37.3 percent remaining progression-free at six months. Median overall survival reached 10.6 months, and 42.7 percent of patients were still alive one year after starting treatment. For a population in which many would previously have had a life expectancy measured in a handful of months, these figures represent a real extension of time, even if they fall short of the dramatic gains seen in earlier treatment settings or in trial populations selected for better baseline health.

Perhaps the most intriguing finding concerns the number of prior treatments. The researchers compared patients who had received three prior chemotherapy lines with those who had received four or more, expecting to see a clear gradient of worsening outcomes with increasing pretreatment. Instead, they found essentially no difference: progression-free survival was 4.1 months in the three-line group versus 3.7 months in the more heavily treated group, and overall survival was 10.5 versus 11.7 months, with neither comparison approaching statistical significance. On its face, this might suggest that the drug works equally well no matter how much treatment a patient has already received—an idea with profound implications for how late in the disease course the drug might be deployed.

The authors themselves, however, urge caution against that interpretation, and their reasoning reveals the subtle statistical traps inherent in real-world evidence. Patients who survive long enough to receive a fourth, fifth, or sixth line of chemotherapy are, by definition, a selected group: they tend to have slower-growing tumors, better performance status, and fewer comorbidities than patients who deteriorate rapidly after their third line. This survivorship bias means the heavily pretreated subgroup starts with an advantage that can mask the true cost of additional prior therapy. Selection bias compounds the problem, because clinicians choose whom to treat with the drug, and those choices are informed by factors that never appear fully in any dataset. The absence of a survival difference across pretreatment groups, the researchers conclude, should not be read as proof of equivalent efficacy regardless of prior exposure.

On the safety front, the study delivered reassuring news. Sacituzumab govitecan was generally well tolerated across the cohort, with no unexpected toxicities emerging and, critically, no grade 5 adverse events—meaning no treatment-related deaths were recorded. This matters because the drug’s known side-effect profile, which includes neutropenia and diarrhea, can be harder to manage in patients whose bone marrow and digestive systems have already been stressed by years of chemotherapy. The fact that a real-world population, typically frailer than trial participants, tolerated the drug without surprises strengthens confidence that the safety data from registration trials translate faithfully to ordinary clinical practice.

The broader significance of the study lies in its geography and its method. Central and Eastern European countries are often underrepresented in global oncology trials, and real-world evidence from the region has been sparse. By assembling a multicenter cohort spanning three countries and dozens of institutions, the CEBCC-102 collaboration has produced data that reflect the actual conditions under which most of the world’s cancer patients are treated: variable resources, diverse patient populations, and treatment decisions made without protocol-mandated eligibility criteria. Such studies cannot replace randomized trials, but they serve as an essential reality check, revealing whether the promise of clinical research survives contact with clinical routine.

For patients with metastatic triple-negative breast cancer and the oncologists who treat them, the practical message is one of cautious optimism. Sacituzumab govitecan retains meaningful activity even after multiple lines of chemotherapy, and it can be given safely to clinically fit patients late in their treatment journey. The drug is not a cure, and the survival gains, while real, remain measured in months. But in a disease where every additional option has historically come at the cost of mounting toxicity and diminishing benefit, a targeted agent that extends life while sparing patients the worst ravages of conventional chemotherapy represents genuine progress—and a template for how antibody-drug conjugates may continue to reshape the treatment of hard-to-target cancers.

Subject of Research: Real-world effectiveness of sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer

Article Title: Sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer: a secondary analysis of the CEBCC-102 real-world cohort

Article References: Marcin, K., Aleksandra, K., Polakiewicz-Gilowska, A., Małgorzata, P., Justyna, Ż., Miloš, H., Renata, S., Hana, Š., Miroslava, M., Agnieszka, M., Karolina, W.-S., Maja, L.-H., Anika, P., Daniel, K., Jan, Š., Iveta, K., Iwona, D., Magdalena, S.-R., Tomasz, C., … Mirosława, P. (2026). Sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer: a secondary analysis of the CEBCC-102 real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17103-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17103-x

Keywords: sacituzumab govitecan, triple-negative breast cancer, antibody-drug conjugate, metastatic breast cancer, real-world evidence, TROP-2, progression-free survival, overall survival, late-line therapy, Central Europe, oncology, chemotherapy